<DOC>
	<DOCNO>NCT01811511</DOCNO>
	<brief_summary>The investigator perform 12-week , randomize , double-blind , placebo-controlled crossover human trial evaluate efficacy safety chungkookjang improvement metabolic syndrome . The investigator measure decrement body fat parameter , include Body Fat Mass , Percent Body Fat , Fat Free Mass , Weight BMI ( body mass index ) , monitor blood pressure .</brief_summary>
	<brief_title>Efficacy Safety Chungkookjang Improvement Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Males female 1829 year old BMI ( body mass index ) ≥ 23 kg/m2 WC ( Waist Circumference ) ≥ 90 ( men ) , WC ( Waist Circumference ) ≥ 85 ( woman ) Able give inform consent Allergic hypersensitive ingredient test product The diagnosis type 1 type 2 diabetes fast glucose ≥ 126mg/dL Systolic pressure ≥ 160mmHg , diastolic pressure ≥ 100mmHg History reaction test product gastrointestinal disease Crohn 's disease gastrointestinal surgery History alcohol substance abuse Participation clinical trial within past 2 month Laboratory test , medical psychological condition deem investigator interfere successful participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>